Small interfering RNAs (siRNAs) are among the most promising therapeutic platforms in
many life-threatening diseases. Owing to the significant advances in siRNA design, many …

Atherosclerotic cardiovascular diseases (ASCVD) are a very important cause of premature
death. The most important risk factor for ASCVD is lipid disorders. The incidence of lipid …

Lipoprotein (a)[Lp (a)] is a well-established risk factor for cardiovascular disease,
predisposing to major cardiovascular events, including coronary heart disease, stroke, aortic …

Cardiovascular (CV) disease is the most common cause of death in Europe. Despite proven
benefits, use of lipid-lowering therapy remains suboptimal. Treatment goals are often not …

Numerous genetic and epidemiologic studies have demonstrated an association between
elevated levels of lipoprotein (a)(Lp [a]) and cardiovascular disease. As a result, lowering Lp …

Lipoprotein (a)[Lp (a)] consists of a low-density lipoprotein-like molecule and an
apolipoprotein (a)[apo (a)] particle. Lp (a) has been suggested to be an independent risk …

Recent updates on therapeutic targeting of lipoprotein(a) wi... : Current Opinion in Cardiology
Recent updates on therapeutic targeting of lipoprotein(a) with RNA interference : Current …

Coronary artery disease (CAD) remains a leading cause of global morbidity and mortality,
necessitating continuous refinement in the management of dyslipidemia, one of its major risk …

Lipoprotein a (Lp (a)) is a lipid biomarker that binds cholesterol and bears independent
cardiovascular risk. Strategies to lower the level of Lp (a) and mitigate such risk are …

In 2020, breast cancer became the most commonly diagnosed cancer worldwide.
Conventional therapies like radiotherapy, chemotherapy and surgery have significant …